Pyxis Oncology, Inc. ( (PYXS) ) has released its Q3 earnings. Here is a breakdown of the information Pyxis Oncology, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pyxis Oncology, Inc. is a clinical-stage oncology company focused on developing innovative therapies for solid tumors, particularly head and neck squamous cell carcinoma, leveraging its expertise in antibody-drug conjugates. In its latest earnings report, Pyxis Oncology highlighted a net loss of $61.5 million for the nine months ending September 30, 2025, compared to a $41.8 million loss in the same period the previous year, reflecting increased research and development expenses. The company reported milestone revenue of $2.8 million from its licensing agreement with Simcere following regulatory approval in China, though overall revenue decreased due to the absence of royalty revenues seen in the prior year. Despite the financial challenges, Pyxis Oncology continues to advance its product candidates, with micvotabart pelidotin being a key focus in early-stage clinical development. Looking ahead, Pyxis Oncology plans to secure additional funding to support its operations and development programs, acknowledging the uncertainty in achieving profitability in the near term.